- One disease or many?
- Who gets IgAN, and what do we know about the origins?
- How do patients present?
- Who is likely to have progressive disease?
- Supportive therapy: One for all and what does it include?
- Who should receive immunosuppression, and if so, which one?
- What novel therapies are on the horizon?
- References
-
1.
Kiryluk K, et al.. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet 2014; 46:1187–1196.
-
2.
Suzuki H, et al.. The pathophysiology of IgA nephropathy. J Am Soc Nephrol 2011; 22:1795–1803.
-
3.
Coppo R, et al.. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int 2014; 86:828–836.
-
4.
Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, , et al.. The Oxford classification of IgA nephropathy: Rationale, clinicopathological correlations, and classification. Kidney Int 2009; 76:534–545.
-
5.
Barbour SJ, et al.. The MEST score provides earlier risk prediction in lgA nephropathy. Kidney Int 2016; 89:167–175.
-
6.
Floege J, Feehally J. Treatment of IgA nephropathy and Henoch-Schönlein nephritis. Nat Rev Nephrol 2013; 9:320–327.
-
7.
KDIGO. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int 2012; 2[Suppl 2]:139–274.
-
8.
Pozzi C, et al.. Corticosteroids in IgA nephropathy: A randomised controlled trial. Lancet 1999; 353:883–887.
-
9.
Rauen T, et al.. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 2015; 373:2225–2236.
-
10.
Smerud HK, et al.. New treatment for IgA nephropathy: Enteric budesonide targeted to the ileocecal region ameliorates proteinuria. Nephrol Dial Transplant 2011; 26:3237–3242.
IgA Nephropathy
Search for other papers by Rosanna Coppo in
Current site
Google Scholar
PubMed
Search for other papers by Jürgen Floege in
Current site
Google Scholar
PubMed
© 2021 American Society of Nephrology | All Rights Reserved
Powered by: PubFactory